1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), provides funding and support to innovative startups and small and medium-sized enterprises (SMEs) in Europe, particularly in the DeepTech sector. Launched to bolster the European entrepreneurial ecosystem, the program aims to help companies with high-risk, high-potential innovations scale their operations, thereby contributing to economic growth and job creation within the EU.

Funding Structure

The EIC Accelerator offers a unique blended finance model, combining grants and equity investments to support innovative projects.

Purpose and Impact

The EIC Accelerator plays a crucial role in the European DeepTech and startup ecosystem by addressing the funding gap that often exists for innovative companies. Many startups face challenges in securing private investment, especially in early-stage development phases. The EIC Accelerator mitigates these challenges by offering a combination of grant funding and equity that incentivizes private investors to participate, ultimately leading to a more vibrant innovation landscape in Europe.

Role in Company Scaling

The EIC Accelerator not only provides financial resources but also offers business coaching, mentorship, and networking opportunities. These resources are vital for companies looking to scale their operations and navigate the complexities of the market. By focusing on innovative technologies, the EIC Accelerator helps companies position themselves competitively within their respective industries, facilitating access to further private funding and partnership opportunities.

Case Study: IMPLICITY and SignalHF

Company Overview: IMPLICITY, based in France, is a pioneering health technology company that specializes in heart failure management solutions. Leveraging advanced AI technologies, IMPLICITY aims to enhance patient outcomes and streamline healthcare processes.

Project Overview: The EIC Accelerator project, titled SignalHF, focuses on the development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AI. The project was submitted for the EIC Accelerator Step 2 proposal on March 13, 2024, and successfully advanced to Step 3, culminating in a winning pitch.

Technology Basics and Background: SignalHF is designed to address the critical challenges associated with heart failure management, a condition that affects millions of patients worldwide. The solution integrates predictive analytics and machine learning algorithms to analyze patient data and provide actionable insights. By harnessing real-time data from various sources, including wearable devices and electronic health records, SignalHF aims to predict potential exacerbations and hospitalizations, enabling timely interventions.

The technology behind SignalHF is rooted in AI and data science, combining clinical expertise with advanced algorithms to transform raw data into meaningful health insights. This approach not only aids healthcare professionals in making informed decisions but also empowers patients to manage their conditions more effectively. By facilitating better communication between patients and healthcare providers, SignalHF aims to improve overall health outcomes and reduce the burden on healthcare systems.

In summary, the EIC Accelerator program serves as a vital resource for innovative companies like IMPLICITY, enabling them to develop groundbreaking solutions such as SignalHF. Through its blended finance model and comprehensive support services, the EIC Accelerator fosters an environment conducive to innovation, ultimately driving advancements in the healthcare sector and beyond.

2 The Funding Rounds

Implicity's Funding and Recent EIC Accelerator Participation

Financing Raised and Funding Rounds:
Implicity, a Paris-based healthcare AI company focused on remote cardiac monitoring, has raised $28.57M total funding across multiple rounds. Its latest disclosed funding round is categorized as "Incubator/Accelerator - V" in available databases, though specific amounts per round remain unclear from publicly indexed sources. Investors include Serena Capital, Karista, XAnge, and BNP Paribas, with additional participation from programs like the AWS ISV Accelerate Program.

While Implicity was specified as an EIC Accelerator winner for the March 13, 2024 deadline (Step 2 submission leading to Step 3 interview success), no direct financial details or confirmation of its selection are explicitly listed in the published results for this cut-off. The March 2024 EIC Accelerator awarded €411 million to 68 companies globally, but company-specific award data is unavailable in the provided materials.

Company Valuations and Exit Events:

• Valuation: Not publicly disclosed. Revenue is estimated at $13.3M annually with ~84 employees (as of latest data).
• Exit Events: No IPO, acquisition, or buyout events are reported for Implicity as of current records.

---

Sources

• EIC Accelerator March 2024 Results
• EIC Accelerator: Statistics and Results from the March 2024 call
• Implicity Competitors & Revenue - Growjo
• Implicity Portfolio Page - XAnge
• Imparency Profile - CB Insights

3 The Press Releases

IMPLICITY: An EIC Accelerator Winner from France

IMPLICITY, a French company, successfully secured funding from the EIC Accelerator program in the March 2024 call. The company submitted its proposal on March 13, 2024, and later advanced to and succeeded in the Step 3 interview phase. However, specific details about IMPLICITY's project, partnerships, technology advancements, or team updates are not available in the current search results.

EIC Accelerator Program Overview

The EIC Accelerator supports innovative startups and SMEs across Europe by providing blended finance, which combines grants and equity investments. This funding model is designed to help companies scale up their high-risk, high-impact innovations. The March 2024 call saw significant interest, with 969 proposals submitted and 68 companies selected for funding.

Press Releases and Updates on Implicity.fr

There are no specific press releases or updates available on Implicity's website (implicity.fr) or social media accounts regarding their participation in the EIC Accelerator program. Typically, companies might publish press releases announcing such achievements, but no such information is readily available for IMPLICITY.

Future Implications

Securing EIC Accelerator funding is a significant milestone for any company, as it validates their innovation and potential for growth. This recognition can also attract additional investors and strategic partners, which could be crucial for IMPLICITY's future developments and expansions.

Conclusion

While detailed information on IMPLICITY is limited, their success in the EIC Accelerator program highlights the company's potential for innovation and growth. For more specific updates or press releases related to IMPLICITY, monitoring their official channels would be advisable.

Sources

• EIC Accelerator: Statistics and Results from the March 2024 call
• The winners of the last EIC Accelerator funding round
• 5 EIC Accelerator Winners in March 2024 Round
• EIC Accelerator Results – February 2025 Update
• Science Journals: Editorial Policies
• Social Media Press Release Guide

4 The Technology Advancements

Implicity's Post-EIC Accelerator Funding Advancements and Current Capabilities

Implicity, a French digital MedTech company specializing in AI-driven remote cardiac monitoring, has demonstrated significant clinical and technological advancements following its activities in early 2024. While direct confirmation of EIC Accelerator funding from the March 13, 2024 cut-off (results announced July 2024) is not explicitly documented in available sources, the company’s recent milestones align with innovations typical of EIC-backed deep-tech firms. Below are their key developments:

Current Capabilities

Implicity’s universal monitoring system (UMS) aggregates and standardizes data from all major cardiac implantable electronic device (CIED) manufacturers, including Abbott, Biotronik, Boston Scientific, and Medtronic. Their platform incorporates FDA-cleared AI algorithms for predictive heart failure management and arrhythmia detection, supporting over 100,000 patients across 200+ medical facilities in the US and Europe.

Recent Advancements

• Clinical Impact: The May 2025-published EVIDENCE-RM study analyzed outcomes for 69,000+ ICD/CRT-D patients, demonstrating a 26% mortality reduction, fewer hospitalizations (-4%), and lower cardiovascular care costs (-17.8%) compared to manufacturer-specific systems.
• AI Enhancements: Implicity previewed a proprietary "Predictive AI in Heart Failure" solution at HRS 2024 (May 16–19), though specific technical details remain undisclosed.
• Research Output: Earlier studies presented at HRS 2023 showed a 22% mortality improvement using their alert-based UMS versus conventional systems, while newer analyses incorporated real-world data via France’s Health Data Hub to validate cost-effectiveness.

Market Traction

The company has expanded its customer base through partnerships like IronRod Health (US market entry) and ongoing collaborations with electrophysiology centers globally. Their technology is operational across clinical workflows without requiring new pilots or demonstrators beyond existing deployments.

Intellectual Property & Publications

No new patents are explicitly cited post-March 2024; however:

• The EVIDENCE-RM study was published in Heart Rhythm (specific issue unspecified).
• Previous findings were presented as late-breaking trials at HRS conferences in both 2023 and early-phase results ahead of HRS 2024.

---

Sources:

• Implicity's EVIDENCE-RM Study Demonstrates Marked Improvement
• EVIDENCE-RM Mortality Reduction Findings
• HRS 2024 Predictive AI Announcement
• US Market Entry via IronRod Health
• HRS 2023 Clinical Trial Outcomes

5 The Partnerships and Customers

IMPLICITY's Strategic Partnerships and Market Positioning IMPLICITY, a French healthtech company specializing in AI-driven remote cardiac monitoring, has established key partnerships to advance its global footprint and technological capabilities. Below is an analysis of its collaborations, customer engagements, and market strategy:

---

Key Partners

• Purpose: Accelerate adoption of Implicity’s heart failure telemonitoring solution globally.
• Impact: Leverages Bayer’s cardiology expertise and medical networks to drive international scalability.

Collaboration Focus: Integrate Withings’ connected devices (e.g., smart scales) for early detection of heart failure decompensation through fluid retention monitoring.

Role: Ensures HIPAA/GDPR compliance for U.S. expansion, enabling secure data handling for pilot programs.

EIT Health supported EU market scaling via the Bridgehead Europe program, while AI for Health fosters AI innovation in healthcare through cross-industry collaboration.

Selected for a 2021 accelerator program to refine U.S.-specific strategies and forge industry connections.

---

Customers

Over a dozen French medical centers use Implicity’s heart failure solution, with plans to expand to U.S. hospitals post-FDA clearance (granted pre-2022).

---

Strategic Outcomes of New Relationships

• Market Positioning: Partnerships with Bayer and Plug and Play bolster Implicity as a global leader in integrated cardiac care solutions, targeting the $50B+ remote patient monitoring sector.
• Technology Advancements: Collaborations with Withings enhance real-time data integration from consumer-grade devices into clinical workflows, improving predictive analytics accuracy. ClearDATA’s involvement ensures regulatory adaptability across jurisdictions.

---

Scaling Mechanisms Through Partnerships

The €21M Series A funding (2022) supports R&D in AI algorithms (e.g., ECG analysis tools) and infrastructure upgrades for multi-device compatibility (pacemakers/ILRs). Bayer’s distribution network aids rapid deployment in new markets like North America/EU/Asia-Pacific regions .

---

Sources

Implicity Launches Heart Failure Solution | Partners | Series A Funding Announcement

6 The Hiring and Company Growth

IMPLICITY: Team Growth and Hiring Strategy Post-EIC Accelerator Funding

As a 2024 EIC Accelerator winner, IMPLICITY has demonstrated consistent growth in the cardiac remote monitoring sector, though specific details about its team expansion following the March 2024 award remain undisclosed. Prior to this funding round, the company had already established itself as a leader in AI-driven cardiac data management, with a headcount estimated between 100–200 employees across offices in Paris, New York City, and San Francisco.

Key Insights on Hiring and Growth

• Recent Funding Context: In April 2022, IMPLICITY raised $23M (€21M) to accelerate international expansion and AI algorithm development. While post-2024 hiring trends are not yet publicized, historical growth patterns suggest prioritization of roles in AI engineering, regulatory compliance, and market expansion teams.
• Scaling Strategy: The company’s focus on democratizing remote cardiac care implies ongoing recruitment for clinical data scientists, product developers, and sales personnel to support its U.S. and European market penetration.
• Leadership Stability: Co-founder Dr. Arnaud Rosier remains CEO, with no reported changes to the executive team. His background as an electrophysiologist continues to drive product innovation aligned with clinical needs.

Future Trajectory

New hires are likely enhancing three core areas:

While recent EIC Accelerator funds will further these efforts, specific hiring metrics or leadership changes post-March 2024 require additional disclosure from the company itself.

---

Sources

• Implicity Careers - Wellfound
• Implicity Overview | SignalHire Company Profile
• IMPLICITY Raises $23M Series A Funding
• About Implicity
• EIT Health Article on IMPLICITY’s €21M Raise

7 The Media Features and Publications

Implicity: A French Innovator in Cardiac Remote Monitoring

Implicity, a French company specializing in remote monitoring solutions for cardiac patients, has been making significant strides in the healthcare industry. Founded by Dr. Arnaud Rosier, Implicity develops a universal platform for monitoring patients with connected pacemakers and implantable defibrillators. This platform leverages AI and machine learning to aggregate data from various cardiac implantable electronic devices (CIEDs), enhancing clinical workflows and patient care.

Media Features and Publications

Implicity has been featured in several publications and media outlets. For instance, the company's innovative approach to cardiac care has been highlighted in interviews and articles discussing the adoption of AI and machine learning in healthcare. Additionally, Implicity's participation in major healthcare events has garnered attention from industry leaders and media alike.

Podcasts and Interviews

Dr. Arnaud Rosier, CEO and Founder of Implicity, has participated in interviews that explore the company's journey and innovations. A notable example is an interview with AiThority, where he discussed the role of AI in healthcare and Implicity's mission to improve cardiac patient monitoring.

Conference and Fair Visits

Implicity actively participates in prominent healthcare conferences. In May 2024, the company attended the Heart Rhythm Society (HRS) conference in Boston, where it unveiled a groundbreaking solution in predictive AI for heart failure. This event marked a significant milestone for Implicity, as it showcased its commitment to advancing cardiac care through innovative technologies.

Involvement in Events

Implicity's involvement in events like HRS 2024 demonstrates its proactive approach to engaging with the global medical community. By launching new solutions and presenting research findings, the company plays a pivotal role in shaping the future of cardiac health management.

EIC Accelerator Funding

Although specific details about Implicity receiving EIC Accelerator funding were not found, the company's involvement in European innovation ecosystems suggests potential participation in such funding opportunities. The European Innovation Council (EIC) supports disruptive innovations across Europe, and companies like Implicity could benefit from these programs due to their innovative healthcare solutions.

Conclusion

Implicity's innovative remote monitoring platform and its participation in major healthcare events underscore its position as a leader in cardiac care technology. The company's commitment to advancing predictive AI in heart failure reflects its dedication to improving patient outcomes and transforming the healthcare landscape.

---

Sources: - Implicity company information, funding & investors

• Implicity company information, funding & investors - Dealroom.co
• Predictions Series 2022: AiThority Interview with Dr. Arnaud Rosier, CEO & Founder at Implicity
• Experience the Pulse of Innovation with Implicity at HRS 2024 in Boston